FFO
HURA

Fortitude Family Office’s TuHURA Biosciences HURA Stock Holding History

Fortitude Family Office’s Portfolio HURA Stock Details HURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-208
Closed -$516 – 2165
2025
Q3 		$516 Buy
+208
New +$547 ﹤0.01% 1800

Other funds holding HURA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $6.15B AUM 22.62% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fortitude Family Office's HURA Position: Q4 2025 in Review

Fortitude Family Office sold out of TuHURA Biosciences (HURA) in Q4 2025, closing a stake of 208 shares — an estimated $516 sold.

Fortitude Family Office first reported a position in HURA in Q3 2025 and held it in 1 quarter. The position peaked at $516 in Q3 2025. 65 funds tracked by Wall St. Rank hold HURA as of Q4 2025.

  • Fortitude Family Office reported no remaining TuHURA Biosciences position as of Q4 2025 after selling out during the quarter.
  • Fortitude Family Office sold 208 TuHURA Biosciences shares in Q4 2025, an estimated $516.
  • Fortitude Family Office first reported a position in TuHURA Biosciences in Q3 2025 and held it in 1 quarter.
  • Fortitude Family Office's TuHURA Biosciences position peaked at $516 in Q3 2025.
  • 65 funds tracked by Wall St. Rank held TuHURA Biosciences as of Q4 2025.

Based on Fortitude Family Office's 13F filing for Q4 2025, filed 15 Jan 2026.